Arvinas Inc. (ARVN)
7.39
0.44 (6.33%)
At close: Apr 14, 2025, 3:59 PM
7.34
-0.75%
After-hours: Apr 14, 2025, 07:56 PM EDT
6.33% (1D)
| Bid | 7.3 |
| Market Cap | 508.57M |
| Revenue (ttm) | 263.4M |
| Net Income (ttm) | -198.9M |
| EPS (ttm) | -2.77 |
| PE Ratio (ttm) | -2.67 |
| Forward PE | -3.83 |
| Analyst | Buy |
| Ask | 7.5 |
| Volume | 1,813,911 |
| Avg. Volume (20D) | 2,145,886 |
| Open | 7.12 |
| Previous Close | 6.95 |
| Day's Range | 6.84 - 7.47 |
| 52-Week Range | 5.94 - 37.38 |
| Beta | 2.32 |
About ARVN
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 27, 2018
Employees 430
Stock Exchange NASDAQ
Ticker Symbol ARVN
Website https://www.arvinas.com
Analyst Forecast
According to 14 analyst ratings, the average rating for ARVN stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 278.63% from the latest price.
Stock ForecastsNext Earnings Release
Arvinas Inc. is scheduled to release its earnings on May 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-52.73%
Arvinas shares are trading lower after the company...
Unlock content with
Pro Subscription
2 months ago
-6.8%
Arvinas shares are trading lower after the company reported worse-than-expected Q4 sales results.
